Survodutide
Survodutide
A dual glucagon/GLP-1 receptor agonist currently in Phase 3 trials. The glucagon component amplifies energy expenditure and liver fat reduction, while GLP-1 handles appetite and insulin effects. Positioned for both obesity and MASH (metabolic fatty liver disease).
$ 250
✓ Significant weight reduction (15–20% in Phase 2)
✓ Potent liver fat reduction (MASH treatment)
✓ Increased energy expenditure
✓ Improved metabolic markers
✓ Dual-pathway synergy for greater fat burning
5–6 days
